Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.

Enabling macrophages to phagocytose tumor cells holds great potential for cancer therapy but suffers from tremendous challenges because the tumor cells upregulate antiphagocytosis molecules (such as CD47) on their surface. The blockade of CD47 alone is insufficient to stimulate tumor cell phagocytosis in solid tumors due to the lack of "eat me" signals. Herein, a degradable mesoporous silica nanoparticle (MSN) is reported to simultaneously deliver anti-CD47 antibodies (aCD47) and doxorubicin (DOX) for cancer chemo-immunotherapy. The codelivery nanocarrier aCD47-DMSN was constructed by accommodating DOX within the mesoporous cavity, while adsorbing aCD47 on the surface of MSN. aCD47 blocks the CD47-SIRPα axis to disable the "don't eat me" signal, while DOX induces immunogenic tumor cell death (ICD) for calreticulin exposure as an "eat me" signal. This design facilitated the phagocytosis of tumor cells by macrophages, which enhanced antigen cross-presentation and elicited efficient T cell-mediated immune response. In 4T1 and B16F10 murine tumor models, aCD47-DMSN generated a strong antitumor effect after intravenous injection by increasing tumor-infiltration of CD8+ T cells. Taken together, this study offers a nanoplatform to modulate the phagocytosis of macrophages for efficacious cancer chemo-immunotherapy.

[1]  Philip M. Kim,et al.  Conjugating Ligands to an Equilibrated Nanoparticle Protein Corona Enables Cell Targeting in Serum , 2022, Chemistry of Materials.

[2]  M. Pittet,et al.  Clinical relevance of tumour-associated macrophages , 2022, Nature Reviews Clinical Oncology.

[3]  Zheng Gu,et al.  Leveraging Macrophages for Cancer Theranostics. , 2022, Advanced drug delivery reviews.

[4]  Ziyang Cao,et al.  A siRNA-Assisted Assembly Strategy to Simultaneously Suppress "Self" and Upregulate "Eat-Me" Signals for Nanoenabled Chemo-Immunotherapy. , 2021, ACS nano.

[5]  Yong Gan,et al.  Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages. , 2021, Nano letters.

[6]  Juan Li,et al.  Fullerenols boosting the therapeutic effect of anti-CD47 antibody to trigger robust anti-tumor immunity by inducing calreticulin exposure , 2021 .

[7]  Christine E. Brown,et al.  Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy , 2021, Frontiers in Immunology.

[8]  M. Gelinsky,et al.  Tailoring Materials for Modulation of Macrophage Fate , 2021, Advanced materials.

[9]  Xiangrui Liu,et al.  Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention , 2020, Advanced functional materials.

[10]  X. Fang,et al.  Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy. , 2020, Biomaterials.

[11]  K. Leong,et al.  Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy. , 2020, Small.

[12]  Xiaoyuan Chen,et al.  Engineering Macrophages for Cancer Immunotherapy and Drug Delivery , 2020, Advanced materials.

[13]  Wenbin Lin,et al.  Nanoscale Metal-Organic Framework Co-delivers TLR-7 Agonists and Anti-CD47 Antibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy. , 2020, Journal of the American Chemical Society.

[14]  Yong Wang,et al.  M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects , 2020, ACS central science.

[15]  Xuesi Chen,et al.  Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers , 2020, Science Advances.

[16]  Aaron J. Johnson,et al.  Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity , 2020, Nature Communications.

[17]  Hai‐Yan Xie,et al.  Responsive exosome nano-bioconjugates for synergistic cancer therapy. , 2019, Angewandte Chemie.

[18]  R. Medzhitov,et al.  Harnessing innate immunity in cancer therapy , 2019, Nature.

[19]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[20]  H. Daldrup-Link,et al.  Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don't eat me’ signals off and ‘eat me’ signals on , 2019, Molecular oncology.

[21]  Xiaoyuan Chen,et al.  In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy. , 2019, ACS nano.

[22]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[23]  S. Trefely,et al.  Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated ‘don’t eat me signal’. , 2018, Nature Immunology.

[24]  I. Weissman,et al.  Programmed cell removal by calreticulin in tissue homeostasis and cancer , 2018, Nature Communications.

[25]  Ding Ding,et al.  Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors. , 2018, ACS nano.

[26]  yang-xin fu,et al.  Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. , 2018, Cell reports.

[27]  Yiyun Cheng,et al.  The fluorination effect of fluoroamphiphiles in cytosolic protein delivery , 2018, Nature Communications.

[28]  D. Waxman,et al.  Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. , 2018, Cancer letters.

[29]  P. Tacnet-Delorme,et al.  Calreticulin Release at an Early Stage of Death Modulates the Clearance by Macrophages of Apoptotic Cells , 2017, Front. Immunol..

[30]  N. Khashab,et al.  Degradability and Clearance of Silicon, Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica Nanoparticles , 2017, Advanced materials.

[31]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[32]  Abhishek D. Garg,et al.  Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma , 2016, Science Translational Medicine.

[33]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[34]  S. Martin,et al.  Danger signalling during cancer cell death: origins, plasticity and regulation , 2013, Cell Death and Differentiation.

[35]  Jens-Peter Volkmer,et al.  Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.

[36]  Jens-Peter Volkmer,et al.  Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.

[37]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[38]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[39]  Ash A. Alizadeh,et al.  Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 , 2010, Science Translational Medicine.

[40]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[41]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[42]  T. Matozaki,et al.  Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. , 2009, Trends in cell biology.

[43]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[44]  W. Janssen,et al.  Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte , 2005, Cell.

[45]  J. Nuutila,et al.  Flow cytometric quantitative determination of ingestion by phagocytes needs the distinguishing of overlapping populations of binding and ingesting cells , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.